title: Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
abstract: OBJECTIVE
  The aim was to evaluate the safety of short antiretroviral treatment interruptions and their virologic and immunologic consequences in HIV-infected adults on highly active antiretroviral treatment (HAART) with suppressed viral replication. The viral efficacy upon reintroduction was also evaluated.
  
  
  METHODS
  All patients with undetectable viral load while on HAART were prospectively followed to detect any treatment interruption. We analysed viral and cellular kinetics, incidence of resistance mutations, clinical outcome and results after therapy resumption.
  
  
  RESULTS
  Twenty patients were included, mean time since HIV diagnosis was 95 months and time with undetectable viral load 16 months. Treatment was interrupted because of adverse effects, cancer, tuberculosis or patient will. Treatment was reintroduced after 4 weeks using, if possible, the same combination. HIV viral load was detectable on day 28 after interruption in 18 patients (90%). Median of CD4 cell count (p25-p75) decreased from 478/mm3 (96-716) to 257/mm3 (118-663) (p=0.5). Resistance mutations were found in 9 patients (45%) after interruptions. Treatment was reintroduced in 14 patients; all of them achieved viral suppression.
  
  
  CONCLUSIONS
  In patients receiving HAART who have undetectable viral load, an interruption, no longer than 4 weeks, due to any intercurrent problem seems to be safe. Response to resumption can usually be achieved. Due to the frequent development of resistance, a genotypic test during interruption might be helpful.
authors.affiliation: Department of Infectious Diseases, Hospital General Universitario de Alicante, Spain.
authors.forename: Rosario
authors.initials: R
authors.lastname: Sanchez
authors.forename: Joaquín
authors.initials: J
authors.lastname: Portilla
authors.forename: Adelina
authors.initials: A
authors.lastname: Gimeno
authors.forename: Vicente
authors.initials: V
authors.lastname: Boix
authors.forename: Coral
authors.initials: C
authors.lastname: Llopis
authors.forename: Jose
authors.initials: J
authors.lastname: Sanchez-Paya
authors.forename: Esperanza
authors.initials: E
authors.lastname: Merino
authors.forename: Maria Luz
authors.initials: ML
authors.lastname: de la Sen
authors.forename: Carlos
authors.initials: C
authors.lastname: Muñoz
authors.forename: Sergio
authors.initials: S
authors.lastname: Reus
authors.forename: Joaquín
authors.initials: J
authors.lastname: Plazas
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D004334:Drug Administration Schedule; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D054303:HIV Reverse Transcriptase / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D013030:Spain; D017211:Treatment Failure; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D054303:HIV Reverse Transcriptase